Home > Personal Investment Vitae
Location: United States
Gender: Female
Asset investment style: Hybrid analysis
Market capitalization:
$7,974,989talentsVirtual portfolio value:
$5,038,772talentsNet overall return per annum:
19.30%AYA current rank order:
#14Asset investment philosophy:
Olivia London trades U.S. stocks with the top #176 to #500 positive alpha signals.
Top 10 profitable stock transactions since January 2020Strategy
| Symbol | Company | Buy | Sell | Share Volume | Return (%) | Profit ($) |
|---|---|---|---|---|---|---|
| RMBL | RumbleOn Inc. Class B Common Stock | $0.36 | $7.95 | 21,280 | +2,108.33% | $161,515 |
| VATE | INNOVATE Corp. Common Stock | $0.53 | $4.14 | 44,545 | +681.13% | $160,807 |
| BQ | Boqii Holding Limited American Depositary Shares representing Class A Ordinary Shares | $0.36 | $3.36 | 47,977 | +833.33% | $143,931 |
| BQ | Boqii Holding Limited Class A Ordinary Shares | $0.36 | $3.36 | 47,977 | +833.33% | $143,931 |
| XBIOW | Xenetic Biosciences Inc. Warrants | $2.00 | $23.16 | 5,273 | +1,058.00% | $111,577 |
| LGVN | Longeveron Inc. Class A Common Stock | $3.45 | $26.25 | 3,044 | +660.87% | $69,403 |
| LSCC | Lattice Semiconductor Corporation Common Stock | $6.97 | $48.04 | 1,078 | +589.24% | $44,273 |
| FIVN | Five9 Inc. Common Stock | $16.31 | $110.10 | 460 | +575.05% | $43,143 |
| GLOB | Globant S.A. Common Shares | $34.57 | $215.99 | 217 | +524.79% | $39,368 |
| HZNP | Horizon Therapeutics Public Limited Company Ordinary Shares | $16.41 | $98.56 | 458 | +500.61% | $37,625 |
| Sum | $955,573 |
Top 10 current stock portfolio positions as of March 2026Strategy
| Symbol | Company | Price | Position | Capitalization |
|---|---|---|---|---|
| STKE | Sol Strategies Inc. Common Shares | $1.33 | 15,603 | $20,751 |
| TRVI | Trevi Therapeutics Inc. Common Stock | $11.92 | 1,733 | $20,657 |
| DC | Dakota Gold Corp. Common Stock | $6.96 | 2,907 | $20,232 |
| PONY | Pony AI Inc. American Depositary Shares | $14.34 | 1,406 | $20,162 |
| CMDB | Costamare Bulkers Holdings Limited Common Stock | $19.08 | 1,054 | $20,110 |
| SCCG | Sachem Capital Corp. 8.00% Notes due 2027 | $23.60 | 851 | $20,083 |
| WTF | Waton Financial Limited Ordinary Shares | $5.03 | 3,978 | $20,009 |
| UMBFO | UMB Financial Corporation Depositary Shares Each Representing a 1/400th Interest in a Share of 7.750% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock Series B | $26.80 | 746 | $19,992 |
| KYIV | Kyivstar Group Ltd. Common Shares | $11.82 | 1,691 | $19,987 |
| OPLN | OPENLANE Inc. Common Stock | $28.51 | 701 | $19,985 |
| Sum | $201,968 |
Top 20 investors
Top 20 influencers
| #1 - #5 | #6 - #10 | #11 - #15 | #15 - #20 |
|---|---|---|---|
| @Andy Yeh Alpha | |||
Top 20 followers
| #1 - #5 | #6 - #10 | #11 - #15 | #15 - #20 |
|---|---|---|---|
| @Bob Hessonwitz | @Vincent Bonsai | @Jack hsu | @Apple |
| @Will | @Darren | @AJ Yeh | @ZimboDave |
| @Luminoalgo | @Sandra Martinazzison | @MRCASH1991 | @Bloom789 |
| @Duke | @Mo | @Amy | @Andy Cheung |
| @TechBull22 | @Ru-Ting Yeh | @Syl_will | @George |
2025-06-21 05:25:00 Saturday ET
President Trump refreshes American fiscal fears, worries, and concerns through the One Big Beautiful Bill Act. The Congressional Budget Office (CBO) estimat
2020-05-14 12:35:00 Thursday ET
Disruptive innovators can better compete against luck by figuring out why customers hire products and services to accomplish jobs. Clayton Christensen, T
2025-10-06 10:27:00 Monday ET
Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund
2017-12-19 09:39:00 Tuesday ET
From Oprah Winfrey to Bill Gates, this infographic visualization summarizes the key habits and investment styles of highly successful entrepreneurs:
2024-01-31 14:33:00 Wednesday ET
The new world order of trade helps accomplish non-economic policy goals such as national security and technological dominance. To the extent that freer
2019-01-10 17:31:00 Thursday ET
The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be